Insights

Market commentary and guides

  • MPL, SHL & CSL – Finding Support

    MPL, SHL & CSL are worth adding to your watch-list. We see the current price levels in these names, at or near new buying…

  • CSL – Outlook

    CSL’s FY17 NPAT guidance implies US$1.38b net profit after tax. The company has purchased 1.4m shares during 2HFY17, of the $500 million share buy-back…

  • CSL and Cochlear – Valuation & Earnings Update

    CSL trades 27x forward earnings. FY18 revenue to grow 5% to US$7b, EBIT +18% to US$2.2b, EPS US$3.60 & DPS US$1.70. This places CSL…

  • CSL: Fully Valued At Current Levels

    The share price of CSL jumped almost 14% to $115.90  this week after surprising the market with a big earnings upgrade. After posting a…

  • Healthcare Algo Buy Signals

    At this point in the market we prefer healthcare names as a sector allocation for new money. Here are the recent buy signals generated…

  • Healthcare – Watch For Buying Interest

    Healthcare names are being sold off due to their high PE ratios and negative sentiment towards the sector, which is permeating from the US…

  • Algo Signal Review

    The algo engine has triggered a number of ASX signals in the last 48 hours. CSL has sold-off and is worth watching, the other…

  • Healthcare Opportunities – add to your watch list

    Within the current sell-off Resmed, Sonic Healthcare & CSL look like reasonable opportunities in a back drop of increased volatility. Here are the entry levels…

  • CSL FY16 Earnings Result

    CSL.ASX reported FY16 revenue of $6.1b on EBITDA of $1.65b. The $500m share buyback is less than conducted in the previous 2 years but…